Dihydrospirorenone (ZK30595): a novel synthetic progestagen--characterization of binding to different receptor proteins
- PMID: 1493716
- DOI: 10.1016/0010-7824(92)90121-9
Dihydrospirorenone (ZK30595): a novel synthetic progestagen--characterization of binding to different receptor proteins
Abstract
Dihydrospirorenone (6 beta, 7 beta, 15 beta, 16 beta-dimethylen-3-oxo-17a-pregn-4-en-21, 17-carbolacton) is a new type of progestin with no other agonistic activities, in particular no estrogenic, androgenic or glucocorticoid activity. Dihydrospirorenone is a potent aldosterone antagonist 8 times as potent as spironolactone and antiandrogenic (0.3 times cyproterone acetate). The aim of the present study is to make a broad characterization of dihydrospirorenone at the receptor level and to discuss the results in comparison to those of established progestins. Kinetic studies of 3H-dihydrospirorenone uptake show a rapid increase in the amount of specific binding during the first three hours. The dissociation of 3H-dihydrospirorenone from the cytoplasmic human uterine progesterone receptor, measured by displacement of labeled steroid with dextran-coated charcoal treatment at 4 degrees C at various times, showed a monophasic or one-component, first order dissociation curve like progesterone. Sucrose density gradient centrifugation of the 3H-dihydrospirorenone-labeled myometrial cytosol showed that the dihydrospirorenone binding components sedimented in the 4S and 8S region which is typical for the progesterone receptor under low salt conditions. The high binding affinity of dihydrospirorenone to the binding sites of the mineralocorticoid receptor of rat kidney with an RBA value of 230% compared to aldosterone is remarkable. This reflects the strong antimineralocorticoid activity of this compound which was evaluated in adrenalectomized rats. Furthermore, competitive studies indicated that dihydrospirorenone also displays high affinity for the androgen and some affinity for the glucocorticoid receptors but no measurable affinity for the estrogen receptor.
Similar articles
-
Gestodene: a novel synthetic progestin--characterization of binding to receptor and serum proteins.Contraception. 1989 Sep;40(3):325-41. doi: 10.1016/0010-7824(89)90096-6. Contraception. 1989. PMID: 2548807
-
The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential.Contraception. 1996 Oct;54(4):243-51. doi: 10.1016/s0010-7824(96)00195-3. Contraception. 1996. PMID: 8922878
-
Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity.Ann N Y Acad Sci. 1995 Jun 12;761:311-35. doi: 10.1111/j.1749-6632.1995.tb31386.x. Ann N Y Acad Sci. 1995. PMID: 7625729
-
The preclinical biology of a new potent and selective progestin: trimegestone.Steroids. 2003 Nov;68(10-13):915-20. doi: 10.1016/s0039-128x(03)00142-9. Steroids. 2003. PMID: 14667983 Review.
-
Pharmacology of different progestogens: the special case of drospirenone.Climacteric. 2005 Oct;8 Suppl 3:4-12. doi: 10.1080/13697130500330382. Climacteric. 2005. PMID: 16203650 Review.
Cited by
-
Differential off-target glucocorticoid activity of progestins used in endocrine therapy.Steroids. 2022 Jun;182:108998. doi: 10.1016/j.steroids.2022.108998. Epub 2022 Mar 7. Steroids. 2022. PMID: 35271867 Free PMC article.
-
Efficacy and safety of drospirenone 2 mg/17β-estradiol 1 mg hormone therapy in Korean postmenopausal women.Obstet Gynecol Sci. 2017 Mar;60(2):213-217. doi: 10.5468/ogs.2017.60.2.213. Epub 2017 Mar 16. Obstet Gynecol Sci. 2017. PMID: 28344964 Free PMC article.
-
Efficacy and safety of combined ethinyl estradiol/drospirenone oral contraceptives in the treatment of acne.Int J Womens Health. 2010 Aug 9;1:213-21. doi: 10.2147/ijwh.s3916. Int J Womens Health. 2010. PMID: 21072290 Free PMC article.
-
Drospirenone, a new progestogen, for postmenopausal women with hypertension.Drugs Aging. 2007;24(6):453-66. doi: 10.2165/00002512-200724060-00002. Drugs Aging. 2007. PMID: 17571911 Review.
-
Systemic sclerosis following oral contraception.Clin Rheumatol. 2005 Jun;24(3):316-7. doi: 10.1007/s10067-004-0963-y. Epub 2004 Jul 14. Clin Rheumatol. 2005. PMID: 15940568 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials